MedTrace Logo

Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

NCT05212597 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-01-28

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of sacubitril-valsartan compared to the combination of ARB/CCB on left ventricular remodeling in patients with chronic aortic valve regurgitation.

Conditions

  • Aortic Valve Insufficiency

Interventions

DRUG

Sacubitril-valsartan

50mg\~100mg twice daily

DRUG

Amlodipine-losartan

amlodipine/losartan 2.5/25mg \~ 5/100mg once daily

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Eun Kyoung Kim, MD, PhD · Heart Vascular Stroke Institute, Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212597 on ClinicalTrials.gov